Subscribe to our newsletter to receive the latest product updates and special offers

Order by Signal Tickers
Filters
Descriptive
Fundamental
Technical
ETF
All
Exchange Index Sector Industry Country
Market Cap. Dividend Yield Float Short Analyst Recom. Option/Short
Earnings Date Average Volume Relative Volume Current Volume Trades
Price Target Price IPO Date Shares Outstanding Float
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#1 / 5 Total
AVTE - Aerovate Therapeutics Inc - Stock Price Chart
TickerAVTE [NASD, RUT]
CompanyAerovate Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap40.64MEPS (ttm)-3.03
P/E-EPS this Y-2.29%
Forward P/E-EPS next Y40.44%
PEG-EPS past 5Y-114.14%
P/S-EPS next 5Y-
P/B0.43EPS Q/Q-25.12%
Dividend-Sales Q/Q-
Insider Own33.29%Inst Own64.74%
Insider Trans-2.65%Inst Trans4.19%
Short Float11.49%EarningsMay 13/a
Analyst Recom3.00Target Price2.25
Avg Volume607.81K52W Range1.50 - 32.42
Jun-18-24Downgrade Wells Fargo Overweight → Equal Weight $35 → $2
Jun-18-24Downgrade TD Cowen Buy → Hold
Jun-18-24Downgrade Evercore ISI Outperform → In-line $27 → $2
Aerovate Therapeutics, Inc. is a biotechnology company which engages in the development of drugs for rare cardiopulmonary disease. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension. The company was founded by Benjamin T. Dake on July 27, 2018 and is headquartered in Waltham, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Verwijs MarinusCHIEF TECHNICAL OFFICERJun 14 '24Option Exercise14.5910,600154,65410,600Jun 14 06:00 PM
Eldridge George ASEE REMARKSJun 14 '24Option Exercise2.1415,00032,10020,022Jun 14 06:00 PM
Eldridge George ASEE REMARKSJun 14 '24Sale25.0315,000375,4505,022Jun 14 06:00 PM
Verwijs MarinusCHIEF TECHNICAL OFFICERJun 14 '24Sale25.0010,600265,0000Jun 14 06:00 PM
Gillies HunterCHIEF MEDICAL OFFICERJun 13 '24Option Exercise2.146,00012,84011,602Jun 14 06:00 PM
EQH - Equitable Holdings Inc - Stock Price Chart
TickerEQH [NYSE]
CompanyEquitable Holdings Inc
CountryUSA
IndustryInsurance - Diversified
Market Cap13.02BEPS (ttm)3.23
P/E12.40EPS this Y33.29%
Forward P/E5.56EPS next Y17.68%
PEG0.65EPS past 5Y1.22%
P/S0.98EPS next 5Y19.00%
P/B27.90EPS Q/Q-32.86%
Dividend2.33%Sales Q/Q42.49%
Insider Own0.48%Inst Own99.94%
Insider Trans-25.03%Inst Trans-0.24%
Short Float1.32%EarningsApr 30/a
Analyst Recom2.00Target Price43.11
Avg Volume2.57M52W Range24.65 - 41.64
Jun-18-24Downgrade UBS Buy → Neutral $40 → $43
Equitable Holdings, Inc. engages in the provision of financial services. It operates through the following segments: Individual Retirement, Group Retirement, Investment Management and Research, Protection Solutions, Wealth Management, Legacy, and Corporate and Other. The Individual Retirement segment includes annuity products, which primarily meet the needs of individuals saving for retirement or seeking retirement income. The Group Retirement segment offers tax-deferred investment and retirement services or products to plans sponsored by educational entities, municipalities and not-for-profit entities, as well as small and medium-sized businesses. The Investment Management and Research segment provides investment management, research and related services. The Protection Solutions segment focuses on life insurance products on attractive protection segments such as VUL insurance and IUL insurance and employee benefits business on small and medium-sized businesses. The Wealth Management segment refers to the discretionary and non-discretionary investment advisory accounts, financial planning and advice, insurance, and annuity products. The Legacy segment consists of capital intensive fixed-rate GMxB business written in the Individual Retirement market prior to 2011. The company was founded by Henry B. Hyde in 1859 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HURD JEFFREY JChief Operating OfficerJun 14 '24Sale39.629,969394,992121,521Jun 17 04:50 PM
HURD JEFFREY JChief Operating OfficerMay 15 '24Sale40.429,969402,945131,093May 17 04:34 PM
BERNSTEIN SETH PSee RemarksMay 02 '24Option Exercise20.81122,6552,552,563241,133May 03 05:00 PM
BERNSTEIN SETH PSee RemarksMay 02 '24Sale38.06152,4735,802,65088,660May 03 05:00 PM
Pearson MarkPresident and CEOApr 15 '24Option Exercise21.3420,000426,800715,025Apr 16 05:00 PM
FSLR - First Solar Inc - Stock Price Chart
TickerFSLR [NASD, S&P 500]
CompanyFirst Solar Inc
CountryUSA
IndustrySolar
Market Cap28.08BEPS (ttm)9.54
P/E27.51EPS this Y75.64%
Forward P/E12.43EPS next Y55.24%
PEG0.47EPS past 5Y41.58%
P/S7.88EPS next 5Y58.00%
P/B4.07EPS Q/Q454.63%
Dividend-Sales Q/Q44.83%
Insider Own5.60%Inst Own90.31%
Insider Trans-2.53%Inst Trans2.01%
Short Float5.57%EarningsMay 01/a
Analyst Recom1.65Target Price283.76
Avg Volume2.70M52W Range129.21 - 306.77
Jun-18-24Downgrade Janney Buy → Neutral
First Solar, Inc. is a solar technology company, which engages in the provision of solar modules. It is involved in the design, manufacture, and sale of cadmium tellurid (CdTe) solar modules, which convert sunlight into electricity. The company was founded by Michael J. Ahearn in 1999 and is headquartered in Tempe, AZ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Widmar Mark RChief Executive OfficerJun 03 '24Sale273.2636,69210,026,45681,861Jun 04 05:34 PM
Dymbort Jason E.General Counsel and SecretaryJun 03 '24Sale273.262,308630,68413,351Jun 04 05:32 PM
Bradley Alexander R.Chief Financial OfficerMay 30 '24Sale274.6916,0514,409,00730,652May 31 07:14 PM
Koralewski MichaelChief Supply Chain OfficerMay 30 '24Sale272.924,6461,267,9867,766May 31 07:12 PM
Sweeney Michael TDirectorMay 30 '24Sale273.504,0001,094,02016,692May 31 07:11 PM
OVID - Ovid Therapeutics Inc - Stock Price Chart
TickerOVID [NASD, RUT]
CompanyOvid Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap55.89MEPS (ttm)-0.72
P/E-EPS this Y-11.45%
Forward P/E-EPS next Y23.16%
PEG-EPS past 5Y18.87%
P/S118.92EPS next 5Y-
P/B0.71EPS Q/Q12.72%
Dividend-Sales Q/Q123.70%
Insider Own18.85%Inst Own60.18%
Insider Trans0.14%Inst Trans2.23%
Short Float4.98%EarningsMay 14/b
Analyst Recom1.40Target Price3.17
Avg Volume529.04K52W Range0.75 - 4.14
Jun-18-24Downgrade Oppenheimer Outperform → Perform
Ovid Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of medicines for patients and families living with rare neurological disorders. The company was founded by Matthew During in April 2014 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LEVIN JEREMY MCEOMar 18 '24Buy2.7618,24850,3643,616,715Mar 20 05:22 PM
ZNTL - Zentalis Pharmaceuticals Inc - Stock Price Chart
TickerZNTL [NASD, RUT]
CompanyZentalis Pharmaceuticals Inc
CountryUSA
IndustryBiotechnology
Market Cap293.98MEPS (ttm)-3.36
P/E-EPS this Y39.51%
Forward P/E-EPS next Y-34.28%
PEG-EPS past 5Y-50.05%
P/S7.25EPS next 5Y-
P/B0.64EPS Q/Q113.26%
Dividend-Sales Q/Q-
Insider Own12.31%Inst Own113.65%
Insider Trans-0.48%Inst Trans-0.93%
Short Float28.13%EarningsMay 07/b
Analyst Recom2.20Target Price12.11
Avg Volume653.22K52W Range8.25 - 30.53
Jun-18-24Downgrade Wells Fargo Overweight → Equal Weight
Jun-18-24Downgrade Wedbush Neutral → Underperform $15 → $4
Jun-18-24Downgrade Morgan Stanley Overweight → Equal-Weight $38 → $8
Jun-18-24Downgrade Jefferies Buy → Hold $42 → $6
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gallagher CamPresident, Interim CFOMay 31 '24Sale11.989,597114,972633,680May 31 06:27 PM
HAUSMAN DIANAChief Medical OfficerMay 09 '24Sale12.623,35642,353373,876May 09 07:46 PM
Epperly Melissa B,Chief Financial OfficerFeb 12 '24Sale11.442,57329,435451,449Feb 12 08:22 PM
Gallagher CamPresidentFeb 12 '24Sale11.441,17313,419643,277Feb 12 08:21 PM
Gallagher CamPresidentFeb 02 '24Sale11.5411,552133,310644,450Feb 05 07:13 PM
1